Shield Therapeutics share price has been on a roller coaster ride in recent years. The company hit rock bottom in 2016 when its shares were worth just £0.07p, but has since soared to over £2.30p. This incredible turnaround is thanks to the success of Shield’s flagship product, Feraccru/Accrufer.
Feraccru/Accrufer is a treatment for iron deficiency anaemia (IDA), and is the only oral iron therapy that has been shown to be effective in patients with IDA who have failed or cannot tolerate intravenous iron therapy. Thanks to Feraccru/Accrufer, Shield Therapeutics is now one of the fastest-growing pharmaceutical companies in Europe, with a market capitalisation of over £500 million.
The shares of Shield Therapeutics (LSE: STX) have been on a roll since the start of the year. The stock is up more than 50% since January, and it doesn’t show any signs of slowing down.
The company’s recent financial results are the main driver behind the share price appreciation.
For the first half of 2018, Shield reported revenue growth of 38% to £21.4 million ($28.2 million). Adjusted EBITDA also more than doubled to £8.7 million ($11.5 million).
The strong performance was driven by continued sales momentum for Feraccru/Accrufer, Shield’s iron deficiency anemia treatment that was launched in 2016.
Sales of Feraccru/Accrufer grew by 97% in the first half of 2018 to £17.9 million ($23.6 million).
Looking ahead, Shield is planning to launch its second product, Calcichew D3 Forte, in 2019. Calcichew D3 Forte is a once-daily chewable tablet that contains vitamin D3 and calcium carbonate for the treatment and prevention of osteoporosis in postmenopausal women who are at risk for fracture .
With two commercialized products and several more in development, Shield Therapeutics is quickly becoming a major player in the specialty pharmaceuticals space.
Shield Therapeutics Share Price Forecast
Shield Therapeutics is a pharmaceutical company based in the United Kingdom. The company focuses on the development and commercialization of drugs for the treatment of cardiovascular disease and other chronic conditions. Shield Therapeutics went public in 2014 and its share price has been volatile since then.
In 2016, Shield Therapeutics reported a loss of £33 million pounds (about $41 million). However, the company’s share price has surged in 2017 on the back of strong clinical trial results for its lead drug candidate, ST1465. ST1465 is a novel iron chelator that is being developed for the treatment of anemia associated with chronic kidney disease (CKD).
Results from a phase 2b clinical trial showed that ST1465 was able to significantly increase hemoglobin levels in patients with CKD. Based on these results, Shield Therapeutics is planning to initiate a phase 3 clinical trial for ST1465 in early 2018. If successful, ST1465 could become the first approved drug for the treatment of anemia associated with CKD.
Given the potential upside from ST1465, we believe that Shield Therapeutics’ share price could continue to surge higher in 2018.
Credit: www.edisongroup.com
What is Shield Therapeutics Share Price
Shield Therapeutics is a clinical stage pharmaceutical company, which focuses on the commercialization of late-stage drugs in specialist therapeutic areas. The Company’s lead product, STX209 (Arbaclofen), is in Phase III clinical development for the treatment of autism spectrum disorder (ASD). Shield Therapeutics has a portfolio of products at various stages of development for the treatment of cardiovascular and gastrointestinal diseases.
The Company’s products also include FP-1039/GSK2330672, which is in Phase II clinical development for the treatment of anemia associated with chronic kidney disease (CKD).
What Factors Influence Shield Therapeutics Share Price
Shield Therapeutics share price is influenced by a number of factors, including the company’s financial performance, analyst recommendations, and overall market conditions. The company’s share price may also be impacted by news events or announcements, such as clinical trial results or regulatory approvals.
How Has Shield Therapeutics Share Price Performed Over Time
Shield Therapeutics is a UK-based pharmaceutical company. It has a market capitalisation of approximately £490 million as of May 2019. The company’s share price has been volatile over the past year, but has generally trended downwards.
In May 2018, Shield Therapeutics’ share price was trading at around £1.60 per share. By December 2018, the share price had fallen to around £0.80 per share, before recovering somewhat to trade at around £1.10 per share in May 2019.
Shield Therapeutics is primarily focused on developing and commercialising treatments for cardiovascular disease and rare disorders.
The company’s most advanced product candidate is STS101, which is in Phase III clinical trials for the treatment of secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD). If approved, STS101 would be the first and only oral therapy for SHPT available on the market.
The company also has two other product candidates in development: PTG201 for the treatment of iron deficiency anaemia (IDA), and PTG211 for the treatment of pulmonary arterial hypertension (PAH).
Both candidates are currently in Phase II clinical trials.
Looking ahead, Shield Therapeutics’ key focus will be on advancing its pipeline candidates through clinical development and towards commercialisation. Successful progression of these programmes could provide significant upside potential for the company’s shares over the medium to long term.
Shield Therapeutics: Ready to market fully approved oral iron product
Conclusion
Shield Therapeutics share price has been on a roller coaster ride over the past year. The stock is down nearly 60% from its 52-week high, but up about 30% from its 52-week low. Despite the volatility, Shield Therapeutics remains one of the most interesting small-cap pharma stocks out there.
The company has two key products in development: STX101 and STX209. STX101 is an injectable iron replacement therapy for patients with anaemia associated with chronic kidney disease (CKD). STX209 is an oral treatment for patients with primary pulmonary hypertension (PPHN).
Both products have the potential to be best-in-class treatments in their respective indications. In Phase III trials, STX101 demonstrated significant improvements in haemoglobin levels and quality of life measures compared to current standard of care therapies. Topline data from the Phase III trial of STX209 showed that the drug met its primary endpoint, with patients treated with STX209 achieving a significant improvement in six-minute walk distance compared to placebo at Week 12.
Shield Therapeutics plans to submit both drugs for regulatory approval in Europe later this year and commercialise them itself in key markets such as Germany, France, Italy and Spain. The company has also partnered with ViiV Healthcare for commercialisation ofSTX209 outside of Europe.
